How to buy Proteostasis Therapeutics stock (PTI)

Proteostasis Therapeutics is a biotechnology business based in the US. Proteostasis Therapeutics shares (PTI) are listed on the NASDAQ and all prices are listed in US Dollars. Proteostasis Therapeutics employs 44 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Proteostasis Therapeutics stock

Buy Proteostasis Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Proteostasis Therapeutics stock price (NASDAQ: PTI)

Use our graph to track the performance of PTI stocks over time.

Proteostasis Therapeutics shares at a glance

• Key figures

Information last updated 2021-02-21.

52-week range	$0.00 - $0.00
50-day moving average more info button	$2.64
200-day moving average more info button	$1.40
Wall St. target price	$5.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.50

Is it a good time to buy Proteostasis Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Proteostasis Therapeutics financials

Gross profit TTM	$5 million
Return on assets TTM	-31.16%
Return on equity TTM	-72.38%
Profit margin	0%
Book value	$0.71
Market Capitalization more info button	$2.9 million

TTM: trailing 12 months

Proteostasis Therapeutics share dividends

We're not expecting Proteostasis Therapeutics to pay a dividend over the next 12 months.

Have Proteostasis Therapeutics's shares ever split?

Proteostasis Therapeutics's shares were split on a 1:20 basis on 22 December 2020 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Proteostasis Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Proteostasis Therapeutics shares which in turn could have impacted Proteostasis Therapeutics's share price.

Proteostasis Therapeutics share price volatility

Over the last 12 months, Proteostasis Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Proteostasis Therapeutics's is 1.1167. This would suggest that Proteostasis Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Proteostasis Therapeutics overview

Proteostasis Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc.

Frequently asked questions

What percentage of Proteostasis Therapeutics is owned by insiders or institutions?
Currently 15.299% of Proteostasis Therapeutics shares are held by insiders and 22.571% by institutions. How many people work for Proteostasis Therapeutics?
Latest data suggests 44 work at Proteostasis Therapeutics. When does the fiscal year end for Proteostasis Therapeutics?
Proteostasis Therapeutics's fiscal year ends in December. Where is Proteostasis Therapeutics based?
Proteostasis Therapeutics's address is: 80 Guest Street, Boston, MA, United States, 02135 What is Proteostasis Therapeutics's ISIN number?
Proteostasis Therapeutics's international securities identification number is: US74373B1098 What is Proteostasis Therapeutics's CUSIP number?
Proteostasis Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74373B109